^
Association details:
| Biomarker: | BIRC3 mutation |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Torisel (temsirolimus) (mTOR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
CORRELATION OF THE MCL35 SCORE AND GENE MUTATIONS WITH OUTCOME IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) TREATED WITH IBRUTINIB IN THE MCL3001 RAY TRIAL
Published date:
06/12/2020
Excerpt:
In the TEM arm, combined mutation/deletion status affecting three genes (BIRC3 [HR 2.2; 95% CI, 1.3-3.6; Q = 0.021], DLGAP2 [HR 2.2; 95% CI, 1.3-3.8; Q = 0.0406], and ARID1B [HR 1.9; 95% CI, 1.2-3.1; Q = 0.051]) was associated with shorter PFS after multiple testing correction.... Mutations in alternative NF-κB pathways and deletions affecting DLGAP2 and ARID1B were linked to shorter PFS with TEM.
Trial ID:
